[See update at bottom of post; Supreme Court ruled 10-1-07.]
A much anticipated Supreme Court ruling potentially impacting every personal injury suit against a medical device maker has been imperiled by a weird procedural wrinkle. Unbeknownst to the lawyers handling the appeal, known as Riegel v. Medtronic, plaintiff Charles Riegel died in December 2004, almost three years ago, and about 20 months before they filed the Supreme Court petition on his behalf.
Riegel sued after a Medtronic balloon catheter burst during an angioplasty in 1996, causing serious injuries. The Supreme Court agreed to hear the Riegel case in November 2006, because it raised the question of whether state law tort suits against medical device makers are preempted — i.e., barred — by certain language contained in the federal regulatory laws governing such devices. (The case does not directly impact suits against pharmaceutical manufacturers, who are regulated under a different federal statute that lacks the specific language in dispute.)
Often when a plaintiff in a personal injury suit dies, his case can survive him so long as the plaintiffs lawyers act promptly to substitute his estate as the new plaintiff. Under the relevant Supreme Court rule, the lawyer is supposed to do so within 6 months of the plaintiff’s death. Medtronic (MDT) is now arguing that because the plaintiffs lawyers didn’t meet that deadline, Riegel’s suit long ago “abated” (i.e., ended) and the appeal must now be dismissed. Though much of the medical device industry — which includes companies like Boston Scientific (BSX) and Johnson & Johnson (JNJ) — is eager for the case to be heard, anticipating a pro-industry ruling, Medtronic won the Riegel case in the courts below, and therefore would like to see this particular appeal dismissed (preserving their victory).
On August 1 Riegel’s appellate counsel at the Public Citizen Litigation Group, Allison Zieve, filed what’s oddly known as a “suggestion of death” motion, in which she sought to substitute Charles Riegel’s wife, Donna — the administrator of Charles’s estate — for Charles as the plaintiff. In her motion papers Zieve wrote that she first learned of Charles’s death from Donna in June of this year, and only managed to have Donna officially appointed as his administrator in late July. Zieve writes that she continually kept the Riegels apprised of the status of the case by writing to Donna, and that Donna, as a lay person, had simply not realized the impact her husband’s death would have on his suit. She argues that the Court has discretion to waive the 6-month rule and that, in any event, Donna was already a co-plaintiff in the case, suing for loss of her husband’s consortium (companionship), so her claim should go forward in any event.
Medtronic argues, on the other hand, that the abatement rule is mandatory and claims that it’s unclear under New York law whether Donna’s consortium claims survive Charles’s death. (The Court likes to hear cases that are unclouded by such state law side-issues.)
While pro-business bloggers have had some fun with the situation — as allegedly reflecting how distantly plaintiffs lawyers are in touch with their clients — to my ears the developments have more of a “there-but-for-the-grace-of-God-go-I” ring to them. I can well imagine a lay person, upon her husband’s death, having other things on her mind than rushing to the surrogate’s court to be formally appointed administrator of his lawsuit.
What do others think?
UPDATE (October 1, 2007, at 3:38) : This morning the Supreme Court allowed the plaintiff to substitute Donna, as administrator for the estate, for Charles. Chief Justice John Roberts and Associate Justice Antonin Scalia dissented. See Drug and Device Log post here.)